RVL Pharmaceuticals plc (O1P.F)
| Previous Close | 0.0030 |
| Open | 0.0030 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0030 - 0.0030 |
| 52 Week Range | 0.0030 - 1.4900 |
| Volume | |
| Avg. Volume | 12,345 |
| Market Cap | 1.896M |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.50 |
GlobeNewswireRVL Pharmaceuticals plc Announces Prepackaged Reorganization of Certain U.S. Subsidiaries
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (“RVL” or “the Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride o
- GlobeNewswire
RVL Pharmaceuticals plc to Present at the H.C. Wainwright 25th Annual Global Investment Conference
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Tuesday, September 12, 2023 Time:11:30 am ET Webcast:Click here To schedule a 1x1 investor meeting with the Company, pl
- GlobeNewswire
RVL Pharmaceuticals plc Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) (“RVL” or the “Company”), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu the
